Nivolumab Boosted Survival in Relapsed Mesothelioma

KEYNOTE-598: Dual PD-1 and CTLA-4 Checkpoint Blockade Confers No Therapeutic Benefit Beyond PD-1 Blockade Alone in PD-L1–Positive NSCLC

LCMC3 Findings Indicate Neoadjuvant Atezolizumab Safe, Efficacious in Resectable Stage IB-IIIB NSCLC

Genetically Tailored Treatment Approach Did Not Improve Survival in Stage II-III NSCLC

IASLC Establishes Global Molecular Database for Thoracic Malignancies: A Call for Data

IASLC Journals Share Exciting Milestones on Metrics Journeys

Renowned Medical Oncologist, Investigator to Take Reins at IASLC in March

Introducing the New ILCN

IASLC’s Global Reach a Strength on the Road to a Cure for Lung Cancer

IASLC Releases Position Statement on Air Pollution on Earth Day

IASLC Responds to Call for Evidence

Renowned Researcher Fred Hirsch Delivers 2022 Heine H. Hansen Award Lecture